NasdaqCM - Nasdaq Real Time Price USD

Achilles Therapeutics plc (ACHL)

Compare

0.9899

+0.0034

(+0.34%)

At close: December 13 at 4:00:00 PM EST

0.9900

+0.00

(+0.01%)

After hours: December 13 at 4:25:17 PM EST

US Penny Stocks To Watch In November 2024

As U.S. markets navigate a mix of earnings reports and geopolitical developments, investors are keenly watching how these factors influence major indices like the Dow Jones, S&P 500, and Nasdaq Composite. For those interested in exploring investment opportunities beyond the usual blue-chip stocks, penny stocks present a unique avenue worth considering. Despite their somewhat outdated moniker, penny stocks can offer significant growth potential when backed by solid financial fundamentals.

Simply Wall St. 26 days ago

ACHL
+0.34%
GRNQ
Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market

LONDON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) today announced that on November 15, 2024, the Listing Qualifications department of the Nasdaq Stock Market LLC ("Nasdaq") approved the Company's request to transfer the listing of the Company's American Depositary Shares (the "ADSs") from the Nasdaq Global Market to the Nasdaq Capital Market. The transfer is expected to take effect at the opening of business on November 19, 2024. The transfer of the Company's lis

GlobeNewswire 26 days ago

ACHL
+0.34%
Achilles Therapeutics Reports Third Quarter 2024 Financial Results

– Cash position of $86.1 million as of September 30, 2024, not including cash R&D tax credit of $12.8 million received in October 2024 – LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) today announced its financial results for the third quarter ended September 30, 2024, and recent corporate updates. Corporate Updates Following the discontinuation of its TIL-based cNeT program and closure of the Phase I/IIa CHIRON and THETIS clinical trials, the Company has enga

GlobeNewswire last month

ACHL
+0.34%
Is Achilles Therapeutics (ACHL) Stock Outpacing Its Medical Peers This Year?

Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.

Zacks 2 months ago

ACHL
+0.34%
BFLY-WS
Achilles Therapeutics Announces Strategic Update

–Achilles to discontinue development of TIL-based cNeT therapy– –Cash position of $95.1 million as of June 30, 2024– –BofA Securities engaged to provide strategic financial advice– LONDON, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) today announced the discontinuation of its TIL-based cNeT program and closure of the Phase I/IIa CHIRON and THETIS clinical trials. The Company will refocus its strategy to explore further engagement with third parties who are developi

GlobeNewswire 2 months ago

ACHL
+0.34%
Will Achilles Therapeutics (NASDAQ:ACHL) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...

Simply Wall St. 3 months ago

ACHL
+0.34%
Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates

– Announced research collaboration with Arcturus Therapeutics to explore second-generation mRNA cancer vaccines using Achilles’ AI-powered, tumor-targeting technology – – Provided interim Phase I/IIa update on the use of cNeT in Advanced NSCLC and Melanoma including first patients with enhanced host conditioning (EHC), with the first three EHC patients showing improved cNeT persistence and engraftment – – Cash position of $95.1 million supports operations through 2025 – LONDON, Aug. 14, 2024 (GL

GlobeNewswire 3 months ago

ACHL
+0.34%
Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines

Combines Achilles’ best-in-class AI-driven, tumor-targeting technology with Arcturus’ world-leading self-amplifying mRNA platform Combined technologies have the potential to generate potent and durable T cell responses in pre-clinical IND-enabling studies LONDON, May 22, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced a research collaboration with

GlobeNewswire 6 months ago

ARCT

ACHL
+0.34%
Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Achilles ADSs will continue to trade on the Nasdaq Global Select Market at this time, and the Company’s operations are not affected by the receipt of the NoticeLONDON, May 17, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today disclosed that the Company received notice on May 16, 2024 from the Nasdaq Stock Market LLC (“Nasdaq”) that

GlobeNewswire 6 months ago

ACHL
+0.34%
Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Evaluating the benefit of enhanced host conditioning with further data expected in 2H 2024 – – Strong cash position of $112.3 million supports operations through 2025 – LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid t

GlobeNewswire 7 months ago

ACHL
+0.34%
Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights

– Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma – – Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024 – – Strong cash position of $131.5 million supports operations through 2025 – LONDON, April 04, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company d

GlobeNewswire 8 months ago

ACHL
+0.34%
Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning

– Improved VELOS™ manufacturing process delivering higher cNeT doses – – Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024 – – First three patients dosed in CHIRON and THETIS with enhanced host chemo-conditioning, along with IL-2 aligned to standard TIL therapy, show improved cNeT persistence and engraftment – LONDON, April 04, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company

GlobeNewswire 8 months ago

ACHL
+0.34%
Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?

Here is how ImmunoGen (IMGN) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.

Zacks 10 months ago

IMGN

ACHL
+0.34%
Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference

LONDON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced that the Company will be presenting at the following conference: 10th Annual Immuno-Oncology 360 Conference (IO360)Speaker: Sergio Quezada, PhD, Chief Scientific OfficerPresentation: Targeting Clonal Neoantigens with Precision Cell TherapiesLocation: New Y

GlobeNewswire 10 months ago

ACHL
+0.34%
Is Acadia Healthcare (ACHC) Stock Outpacing Its Medical Peers This Year?

Here is how Acadia Healthcare (ACHC) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year.

Zacks 10 months ago

ACHC

ACHL
+0.34%
Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction

Newly developed computational tools and large datasets with low bias will lead to robust neoantigen prediction and improved personalized cancer therapiesLONDON, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced publication of a ‘Comment’ in Nature Cancer that outlines the vast potential of neoantigen immunogenici

GlobeNewswire 11 months ago

ACHL
+0.34%

Performance Overview

Return	ACHL	MSCI WORLD
YTD	+11.35%	+20.45%
1-Year	+15.10%	+22.00%
3-Year	-77.76%	+21.64%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Achilles Therapeutics plc (ACHL)

US Penny Stocks To Watch In November 2024

Achilles Therapeutics Receives Approval to Transfer to Nasdaq Capital Market

Achilles Therapeutics Reports Third Quarter 2024 Financial Results

Is Achilles Therapeutics (ACHL) Stock Outpacing Its Medical Peers This Year?

Achilles Therapeutics Announces Strategic Update

Will Achilles Therapeutics (NASDAQ:ACHL) Spend Its Cash Wisely?

Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates

Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines

Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights

Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning

Is ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?

Achilles Therapeutics to Present at the 10th Annual Immuno-Oncology 360 Conference

Is Acadia Healthcare (ACHC) Stock Outpacing Its Medical Peers This Year?

Achilles Therapeutics Announces Publication of Nature Cancer ‘Comment’ on Strategy for Improved Neoantigen Immunogenicity Prediction

Performance Overview